TOGETHER WE CAN DO SO MUCH: MULTIDISCIPLINARY SHOCK TEAMS FOR MANAGEMENT OF PATIENTS WITH CARDIOGENIC SHOCK (CCC-141)

Thursday, October 26, 2023

16:30 – 17:15 EST

Location: Palais, 524C

Target Audience: Critical care practitioners, Trainee (clinical), Heart failure specialists

Co-Chair(s)

Craig Ainsworth, MD FRCPC (he/him/his)

Associate Professor of Medicine
CANCARE
McMaster University
Christopher B. Fordyce, MD (he/him/his)

Associate Professor
University of British Columbia
Division of Cardiology, University of British Columbia

Presenter(s)

Faizan Amin, MD, FRCPC

Assistant Professor
CANCARE, CHFS, CCTN
McMaster University
Andrew Kochan, MD, FRCPC

Physician
University Of Toronto
University of Toronto
Adriana Luk, MD, MSc, FRCPC (she/her/hers)

Critical Care Cardiologist, Advanced Heart Failure and Transplantation
University Health Network
University Health Network

PDF
Rebecca Mathew, MD FRCPC

Critical Care Cardiologist
University of Ottawa Heart Institute
University of Ottawa Heart Institute
DS

Derek YF So, MD FRCPC (he/him/his)

Professor, Staff Interventional Cardiologist
University of Ottawa Heart Institute
University of Ottawa Heart Institute
Hadi Toeg

Assistant Professor in Cardiac Surgery
University of Ottawa Heart Institute
University of Ottawa Heart Institute

Planning Committee Member(s)

Rachel Eikelboom

Cardiac Surgery Resident
McMaster University
McMaster University
LG

Laura Goodliffe, MD MPH

Critical Care Fellow
Iqbal H. Jaffer, MBBS PhD FRCSC (he/him/his)

Cardiac Surgeon
Hamilton Health Sciences
McMaster University
PL

Patrick R. Lawler, MD, MPH, FRCPC

Associate Professor
CANCARE
Michael B. Tsang, MD, FRCPC, MSc

Associate Professor, Division of Cardiology, Department of Medicine
CAIC
McMaster
Sean van Diepen, MD, MSc

Physician
University of Alberta
University of Alberta

Disclosure(s):

Craig Ainsworth, MD FRCPC: No financial relationships to disclose

Christopher B. Fordyce, MD: Amgen: Consultant/Advisory Board (Ongoing); Bayer: Consultant/Advisory Board (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing); HLS Therapeutics: Speaker/Honoraria (Ongoing); New Amsterdam: Consultant/Advisory Board (Ongoing); Novartis: Consultant/Advisory Board (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Pendopharm: Consultant/Advisory Board (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Faizan Amin, MD, FRCPC: No financial relationships to disclose

Andrew Kochan, MD, FRCPC: No financial relationships to disclose

Adriana Luk, MD, MSc, FRCPC: No financial relationships to disclose

Rebecca Mathew, MD FRCPC: No financial relationships to disclose

Derek YF So, MD FRCPC: HLS Therapeutics: Consultant/Advisory Board (Ongoing); JAMP Pharma: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Medtronic Canada: Speaker/Honoraria (Ongoing)

Hadi Toeg: No financial relationships to disclose

Michael B. Tsang, MD, FRCPC, MSc: Abiomed: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Boston Scientific: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Teleflex: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)

Sean van Diepen, MD, MSc: No financial relationships to disclose

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

understand the multidisciplinary approach cardiogenic shock teams bring to the management of critically ill cardiac patients;
review cardiogenic shock team protocols;
recognize the potential benefits to initiating a cardiogenic shock team; and
appreciate how to develop a multidisciplinary cardiogenic shock team at their own institution.

Workshop Description: Cardiogenic shock (CS) stems from cardiac dysfunction leading to hemodynamic instability and systemic hypoperfusion. CS is associated with significant morbidity and high mortality rates despite advances in coronary reperfusion, medical therapies and mechanical circulatory support. More recently, some institutions have developed cardiogenic shock teams who provide rapid identification of patients in cardiogenic shock, early interventions and resuscitation and multidisciplinary management of these complex patients. These teams are often made up of Interventional Cardiologists, Cardiac Surgeons, Critical Care Physicians, Advanced Heart Failure Clinicians and Cardiac Anesthesiologists. Preliminary studies have demonstrated that such a cardiogenic shock team-based approach help to expedite the diagnosis of cardiogenic shock, optimize medical therapies and invasive management and possibly improve clinical outcomes in these patients.

This workshop is designed for clinicians who manage patients with cardiogenic shock and clinical teams that may be considering developing a cardiogenic shock team at their institution.